sorafenib has been researched along with bms 214662 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (bms 214662) | Trials (bms 214662) | Recent Studies (post-2010) (bms 214662) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 49 | 8 | 9 |
| Protein | Taxonomy | sorafenib (IC50) | bms 214662 (IC50) |
|---|---|---|---|
| GTPase HRas | Homo sapiens (human) | 0.0013 | |
| GTPase KRas | Homo sapiens (human) | 0.7723 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 0.3617 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.0021 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniecki, C; Priefer, R | 1 |
1 review(s) available for sorafenib and bms 214662
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |